Skip to content
Open access · CC-BY via OpenAlex

Raloxifene is a Female-specific Proteostasis Therapeutic in the Spinal Cord

Edmund Charles Jenkins, Gabriella Casalena, Maria Gomez-Jenkins, Dazhi Zhao, Timothy C. Kenny, Nagma Shah, Giovanni Manfredi, Doris Germain

Endocrinology · 2020 · ▲ 5 citations

Abstract

Several neurodegenerative disorders are characterized by proteasome dysfunctions leading to protein aggregations and pathogenesis. Since we showed that estrogen receptor alpha (ERα) activates the proteasome, drugs able to stimulate ERα in the central nervous system (CNS) could hold potential for therapeutic intervention. However, the transcriptional effects of selective estrogen receptor modulators (SERMs), such as tamoxifen and raloxifene, can be tissue specific. A direct comparison of the effects of different SERMs on gene transcription in the CNS has never been performed. Here, we report an RNA-seq analysis of the spinal cord treated with estrogen, tamoxifen, or raloxifene. We find stark SERM and sex-specific differences in gene expression profiles in the spinal cord. Notably, raloxifene, but not estrogen or tamoxifen, modulates numerous deubiquitinating enzymes, proteasome subunits and assembly factors, and these effects translate into decreased protein aggregates. In the SOD1-G93A mouse model of amyotrophic lateral sclerosis, we found that even a low dose of raloxifene causes a significant decrease in mutant SOD1 aggregates in the spinal cord, accompanied by a delay in the decline of muscle strength in females, but not in males. These results strongly indicate SERM-selective as well as sex-specific effects, and emphasize the importance of sex as a biological variable to be considered for the careful selection of specific SERM for use in clinical trials for neurodegenerative diseases.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1210/endocr/bqaa221
Canonical
link ↗
Fetched
2026-10-27 MST

Cite this

APA
Jenkins, E.C., Casalena, G., Gomez-Jenkins, M., Zhao, D., Kenny, T.C., Shah, N., Manfredi, G., &amp; Germain, D. (2020). Raloxifene is a Female-specific Proteostasis Therapeutic in the Spinal Cord. <em>Endocrinology</em>. https://doi.org/10.1210/endocr/bqaa221
Vancouver
Jenkins EC, Casalena G, Gomez-Jenkins M, Zhao D, Kenny TC, Shah N, et al. Raloxifene is a Female-specific Proteostasis Therapeutic in the Spinal Cord. Endocrinology. 2020. doi:10.1210/endocr/bqaa221.
BibTeX
@article{edmund2020Raloxi, title = {Raloxifene is a Female-specific Proteostasis Therapeutic in the Spinal Cord}, author = {Edmund Charles Jenkins and Gabriella Casalena and Maria Gomez-Jenkins and Dazhi Zhao and Timothy C. Kenny and Nagma Shah and Giovanni Manfredi and Doris Germain}, journal = {Endocrinology}, year = {2020}, doi = {10.1210/endocr/bqaa221}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings